AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology. AbCellera uses the transgenic animal technology to generate fully human monoclonal antibodies for its drug discovery programs with biotech and pharma partners. The United States Patent and Trademark Office (USPTO) issued patent no. 10,881,084 titled “Transgenic Animals and Methods of Use” to Trianni, Inc. (Trianni), an AbCellera Company.

“This patent is an important addition to our IP portfolio, providing protection to our proprietary technology in the U.S.,” said Carl Hansen, Ph.D., CEO of AbCellera and Trianni. “By generating fully human antibodies in the first step of the discovery process, we’re able to increase the speed and efficiency of our partners’ programs to develop therapeutic antibodies.”

Trianni’s genetic engineering technology, which AbCellera acquired in November 2020, is an advanced transgenic platform for developing mice that produce human antibodies. The flagship Trianni Mouse® platform was designed to maximize immune responses, increase antibody diversity, and preserve natural maturation of fully human antibodies. It is also a core platform for quickly developing increasingly powerful transgenic mouse technologies for use in partner programs.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

About Trianni, Inc.

Trianni, an AbCellera company, specializes in antibody discovery technology using transgenic mice. Trianni’s lead technology, the Trianni Mouse®, is a next-generation platform enabling efficient generation of diverse, fully human monoclonal antibodies. The Trianni transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic engineering technology. Additional information about Trianni is available at www.trianni.com.

AbCellera Forward-looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210119006096/en/

Inquiries
Media: Jessica Yingling, Ph.D., [email protected], +1(236)521-6774
Business Development: Kevin Heyries, Ph.D., [email protected], +1(604)559-9005
Legal Affairs: Tryn Stimart, J.D., [email protected], +1(604) 559-9005
Investor Relations: Melanie Solomon, [email protected], +1(778)729-9116